← Leaderboards
Monica L Guzman
University Of Virginia
$6,874,300
Attributed
$13,626,235
Total exposure
9
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,626,235 · 9
By mechanism
R01$9,496,002 · 4
DP2$2,535,000 · 1
R21$1,295,258 · 3
R41$299,975 · 1
Top collaborators
- Katherine L B Borden6 shared
- John Hackett Bushweller5 shared
- Lucio H. Castilla5 shared
- Gabriela Chiosis5 shared
- Mark P. Dunphy5 shared
- Jason S Lewis5 shared
- Guido Marcucci5 shared
- Roger A Rajewski5 shared
Most similar at University Of Virginia
Same institution · by research overlap
- Lucio H. Castilla$7,520,870
- John Hackett Bushweller$17,127,098
- Roger A Rajewski$1,702,496
- Golam Mohi$10,072,497
- Grant C Bullock$672,806
Others in their field
Top investigators on “Clinic”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,108,147,906
- Leonard Freedman · Leidos Biomedical Research, Inc.$978,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$798,941,641
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$639,436,363
- Barton F Haynes · Duke University$546,907,423
Research focus
ClinicPharmaceutical PreparationsMutationMouse ModelMalignant NeoplasmsComplexChemotherapyResponseMolecularBaseProteinsAcute Myelocytic LeukemiaCellsFuturePhenotypeRelapsePathway InteractionsSamplingNovel Therapeutic InterventionStructureDisease RemissionNovel TherapeuticsLeukemiaSuccess
Grant awards (28)
Molecular Mechanisms of eIF4E Mediated Transformation$397,035
R01 · FY2025 · CA
Molecular Mechanisms of eIF4E Mediated Transformation$276,965
R01 · FY2024 · CA
Molecular Mechanisms of eIF4E mediated transformation$1
R01 · FY2024 · CA
Targeted Small Molecule Inhibitors for Inv(16) Leukemia$666,852
R01 · FY2023 · CA
Molecular Mechanisms of eIF4E mediated transformation$291,544
R01 · FY2023 · CA
Targeted Small Molecule Inhibitors for Inv(16) Leukemia$667,159
R01 · FY2022 · CA
Molecular Mechanisms of eIF4E mediated transformation$285,712
R01 · FY2022 · CA
Targeted Small Molecule Inhibitors for Inv(16) Leukemia$678,851
R01 · FY2021 · CA
Molecular Mechanisms of eIF4E mediated transformation$293,545
R01 · FY2021 · CA
Clonal Hematopoeisis in HIV and Aging$254,250
R21 · FY2021 · AG
Targeted Small Molecule Inhibitors for Inv(16) Leukemia$675,954
R01 · FY2020 · CA
3D co-culture system to characterize and target leukemia stem cells$435,827
R21 · FY2020 · CA · contact PI
Clonal Hematopoeisis in HIV and Aging$211,875
R21 · FY2020 · AG
Targeted Small Molecule Inhibitors for Inv(16) Leukemia$716,817
R01 · FY2019 · CA
Preclinical studies of Selective and Orally Bioavailable Aurora B Inhibitors for the Treatment of AML$299,975
R41 · FY2018 · CA
Biomarkers for predicting response to Hsp90 therapy$572,232
R01 · FY2017 · CA
Pharmacological modulation of epigenetic changes in AML$342,107
R01 · FY2017 · CA
Biomarkers for predicting response to Hsp90 therapy$573,509
R01 · FY2016 · CA
Pharmacological modulation of epigenetic changes in AML$342,107
R01 · FY2016 · CA
Biomarkers for predicting response to Hsp90 therapy$599,324
R01 · FY2015 · CA
Pharmacological modulation of epigenetic changes in AML$359,607
R01 · FY2015 · CA
Biomarkers for predicting response to Hsp90 therapy$550,587
R01 · FY2014 · CA
Pharmacological modulation of epigenetic changes in AML$300,948
R01 · FY2014 · CA
Biomarkers for predicting response to Hsp90 therapy$582,268
R01 · FY2013 · CA
Pharmacological modulation of epigenetic changes in AML$322,878
R01 · FY2013 · CA
A role for elevated autophagy in survival and chemoresistance of leukemia stem ce$172,761
R21 · FY2013 · CA · contact PI
A role for elevated autophagy in survival and chemoresistance of leukemia stem ce$220,545
R21 · FY2012 · CA · contact PI
Selection of Novel Therapies to Ablate Chemoresistant Myeloid Leukemia Stem Cell$2,535,000
DP2 · FY2010 · OD · contact PI